JPRN-UMIN000029332已完成未知
Multicenter Survey of subcutaneous induration and effect on glycemic control by the guidance of site rotation in the elderly insulin-injecting patients with diabetes - Multicenter Survey of subcutaneous induration and effect on glycemic control by the guidance of site rotation in the elderly insulin-injecting patients with diabetes
JA Onomichi general Hospital Department of pharmacy0 个研究点目标入组 100 人开始时间: 2017年10月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1,Patient who the attending physician judged impossible to participate 2,Unreceived informed consent
研究者
相似试验
未知
3 期
Study to assess the efficacy, safety and tolerability of secukinumab in Japanese subjects with GPPGeneralized Pustular Psoriasis (GPP)JPRN-jRCT2080222256ovartis Pharma K.K.
已完成
不适用
A randomised study of continuous subcutaneous insulin infusion (CSII) therapy compared to conventional bolus insulin treatment in preschool aged children with Type 1 diabetesNutritional, Metabolic, EndocrineInsulin-dependent diabetes mellitusDiabetesISRCTN77773974Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)20
未知
4 期
A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine APlaque PsoriasisJPRN-jRCT1080222997ovartis Pharma K.K.
进行中（未招募）
1 期
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimensMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2017-004203-41-ESJanssen-Cilag International N.V.180
进行中（未招募）
1 期
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimensMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2017-004203-41-GBJanssen-Cilag International N.V.180